Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer: Comparison of Conventional Variables in Risk Stratification
This study investigated the biomarker potential of glutamine among known prognostic variables in localized prostate cancer.
Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics
Experts in the field review integration of approved PARP inhibitors into advanced prostate cancer clinical practice.